Patient with chronic radiotherapy-induced abdomino-pelvic complications refractory to standard therapy: 12 patients suffering of PRD (LENT-SOMA scale>2)

Pelvic Radiation Therapy

Radiation-induced Hemorrhagic Cystitis

12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections

Mesenchymal Stromal Cell (MSC) injections

Hématologie et thérapie cellulaire, Hôpital Saint Antoine

Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

Clinical Phase II Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

Decrease of one grade for rectorrhagia or hematuria on the LENT SOMA scale (Late Effects Normal Tissue Task Force -Subjective, Objective, Management, Analytic), 4 months after the first injection of MSCs.

Frequency of drug consumption (analgesic, opiate)

Quality of life evaluated by SF36 questionnaire (short form survey)

Quality of life evaluated by questionnaire Hospital Anxiety and Depression Scale (HADS)

Mean pain intensity evaluated by Visual Analogue Scale (VAS) during the week prior to the visit.

Assistance Publique - Hôpitaux de Paris

325mg ASA OD during course of chemotherapy

Hearing Loss

Ototoxicity

325mg ASA OD for the duration of the cisplatin

salicylate/rintasyöpä

Trial Evaluating the Efficacy of Systemic Mesenchymal Stromal Cell (MSC) Injections for the Treatment of Severe and Chronic Radiotherapy-induced Abdomino-pelvic Complications (Pelvic Radiation Disease, PRD) Refractory to Standard Therapy

Does Aspirin Have a Protective Role Against Chemotherapeutically Induced Ototoxicity?

Täydellisin lääketieteellinen tietokanta tieteen tukemana